Clinical trials have also confirmed that the effectiveness of targeted drugs such as CTLA-4 and PD-1 alone or in combination with other drugs is limited for patients with advanced GC, which is far less than that of melanoma, lung cancer and other tumors (Kooshkaki et al., 2020). This evidence concerns the gene CTLA4 and gastric cancer.